Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have received a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $41.00.

A number of analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th.

Insider Transactions at Enliven Therapeutics

In related news, Director Richard A. Heyman sold 9,635 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $25.03, for a total value of $241,164.05. Following the completion of the transaction, the director owned 25,545 shares of the company’s stock, valued at approximately $639,391.35. This trade represents a 27.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Anish Patel sold 48,300 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the transaction, the chief operating officer owned 215,011 shares of the company’s stock, valued at approximately $6,018,157.89. This trade represents a 18.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 259,280 shares of company stock valued at $6,635,968 over the last quarter. 25.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently made changes to their positions in the company. Commodore Capital LP raised its position in Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after purchasing an additional 17,809 shares during the period. Polar Capital Holdings Plc increased its stake in shares of Enliven Therapeutics by 1.5% during the third quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock valued at $63,355,000 after buying an additional 44,713 shares during the period. Vanguard Group Inc. raised its holdings in shares of Enliven Therapeutics by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after purchasing an additional 142,378 shares in the last quarter. Vestal Point Capital LP raised its stake in Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after buying an additional 910,000 shares in the last quarter. Finally, Duquesne Family Office LLC raised its position in shares of Enliven Therapeutics by 104.6% in the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after acquiring an additional 484,405 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $26.45 on Tuesday. The stock has a fifty day moving average of $20.83 and a 200 day moving average of $20.49. Enliven Therapeutics has a one year low of $13.30 and a one year high of $29.98. The stock has a market cap of $1.57 billion, a PE ratio of -14.37 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. As a group, sell-side analysts predict that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.